Skip to main content
Ir a la página de inicio de la Comisión Europea (se abrirá en una nueva ventana)
español es
CORDIS - Resultados de investigaciones de la UE
CORDIS
Contenido archivado el 2024-06-18

Pharmacodynamic Approaches to Demonstration of Disease-Modification in Huntington’s Disease by SEN0014196

Objetivo

The Consortium will undertake clinical research activities aimed at ascertaining feasibility of a range of pharmacodynamic readouts for use in the clinical development of SEN0014196 to demonstrate the disease-modifying properties of the compound in Huntington’s Disease. SEN0014196 is a novel and selective SirT1 inhibitor, currently in Phase I clinical development, and enjoys Orphan Status in the EU as of September 2, 2009. A multi-factorial approach will be used, including assessment of both novel and compound-specific measures of molecular action as well as previously identified predictors of disease progression. The translational approaches addressed by this project are instrumental in the progression of SEN0014196 to clinical proof-of-concept and, if successful, will play a pivotal role in patient stratification and outcomes research. The Consortium will comprise four partners, all with a proven track-record in Research and Development in the Huntington’s Disease area. All Partners are based within the EU.

Ámbito científico (EuroSciVoc)

Este proyecto aún no se ha clasificado con EuroSciVoc.
Sugiera los ámbitos científicos que considere más relevantes y ayúdenos a mejorar nuestro servicio de clasificación.

Programa(s)

Tema(s)

Convocatoria de propuestas

FP7-HEALTH-2010-single-stage
Consulte otros proyectos de esta convocatoria

Régimen de financiación

CP-FP - Small or medium-scale focused research project

Coordinador

SIENA BIOTECH SPA
Aportación de la UE
€ 1 540 673,73
Dirección
Via Banchi di Sotto 34
53100 SIENA
Italia
Tipo de actividad
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Enlaces
Coste total
Sin datos

Participantes (4)